Subject
Cancer Research,Oncology,Hematology
Reference7 articles.
1. In vitro cardiotoxicity potential comparative assessments of chronic myelogenous leukemia tyrosine kinase inhibitor therapies: dasatinib, imatinib and nilotinib;Freebern,2007
2. Preclinical evaluation of potential nilotinib cardiotoxicity;Wolf;Leuk Res,2011
3. Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz JA, Larson RA, Gattermann N, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011 Jan 27;117(4):1141-5. Epub 2010 Nov 22.
4. Larson RA, Hochhaus A, Saglio G, Rosti G, Lopez JL, Stenke L, et al. Cardiac safety profile of imatinib and nilotinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): results from ENESTnd. ASH Annual Meeting Abstracts 2010;116:2291.
5. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate;Kerkela;Nat Med,2006
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献